Home
 /
Papers
 /
Immunology
 /
Consistent Induction of Broadly Neutralizing HIV Antibodies by a Novel Two-Step Mechanism Informs Immunogen Design
Preprint
Open access
Top 1% · Validated by QED

Consistent Induction of Broadly Neutralizing HIV Antibodies by a Novel Two-Step Mechanism Informs Immunogen Design

Ashwin N. Skelly, Harry B. Gristick, Hui Li +54 more
October 2025
 ·
bioRxiv
 ·
DOI 
10.1101/2025.10.06.680687
99
%
QED Score
QED Impressions

By achieving consistent, rapid V3-glycan bNAb induction in 64% of outbred macaques through a defined two-step mechanism, this work dismantles HIV vaccinology's most persistent barrier and delivers a concrete molecular blueprint for vaccine design.

Run full QED analysis
Read paper
Save

QED claims analysis

Summary

A novel epitope-focused SHIV strain (SHIV.5MUT) rapidly and consistently induces potent V3-glycan broadly neutralizing antibodies in 64% of infected macaques through a two-step mechanism in which V1-directed antibodies select for viral variants with shortened, hypoglycosylated V1 loops that expose the underlying V3-glycan epitope to prime diverse bNAb precursors, which then mature to breadth through coevolution with viral quasispecies that sample key resistance mutations found in global HIV-1 strains, providing the first reproducible outbred animal model of bNAb induction and a molecular blueprint for sequential vaccine design.

See full analysis
Main Claim 1 –

SHIV.5MUT Rapidly and Consistently Induces V3-Glycan bNAbs

Supporting evidence

  • SHIV.5MUT Elicits Diverse V3-Glycan bNAbs Resembling Human bNAbs
  • SHIV.5MUT bNAbs Show Human-Like Structural Diversity and Approach Angles
  • SHIV.5MUT bNAb UCAs Are Traceable and Human Allele-Like
Main Claim 2 –

SHIV.5MUT Drives V1 Selection Before V3 Selection in bNAb Developers

Supporting evidence

  • Ten Env Sites and V1h Changes Enriched in bNAb Developers
  • Quasispecies Resistance Mutations Precede or Coincide with Breadth Acquisition
Main Claim 3 –

Two-Step SHIV.5MUT Mechanism: V1 Antibodies Expose V3-Glycan Epitope

Abstract

A major obstacle confronting HIV-1 vaccine and cure research is the lack of an outbred animal model for rapid and consistent induction of broadly neutralizing antibodies (bNAbs). We designed an epitope-focused simian-human immunodeficiency virus (SHIV.5MUT) that elicited broad and potent V3-glycan-targeted antibodies within a year of infection in 14 of 22 macaques compared with 0 of 14 control animals. SHIV.5MUT elicited bNAbs by a novel two-step mechanism, inducing an initial wave of V1-directed antibodies that selected for Envs with shortened, hypoglycosylated V1 loops, which in turn primed V3-glycan bNAb precursors. Rhesus bNAbs were immunogenetically and structurally diverse, closely resembling human V3-glycan bNAbs. Env-bNAb coevolution revealed a diverse repertoire of bNAb precursors and the Env variants that matured them, yielding a molecular blueprint for vaccine design.

Related papers

How the QED Score works

QED Score is an AI-based quality metric for life science research. It rates each paper on two dimensions: originality (is the finding new and important?) and validity (does the evidence support the claims?). Author names and affiliations are removed before scoring. Each manuscript is broken down into its claims and the experiments behind them, and specialized AI agents then examine those claims for statistical rigor, consistency across figures, and contradictions with the existing literature. A verification layer re-checks every issue they flag. Scores are percentile ranks against all papers in the corpus. In a blinded study of papers where QED Score and journal rank disagreed, domain experts sided with QED Score in 75% of cases.
Read the methodology

Free access for academic researchers

Create your free QED account to validate your research, strengthen grant proposals, and uncover scientific insights.
We've sent you an access link.
Please check your inbox.

Didn't get your email? Check your spam folder or reach out to info@qedscience.com

Oops! Something went wrong while submitting the form.
Looking for QED for pharma, biotech or life science organizations?